roche glp-1 ADA '26: Lilly's dominance, Pfizer's 'foundational' drug and Roche's 'me-too' option Roche's GLP1/GIP drug sees 22.5%

Branded partnerships, alternative weight-loss therapies, and expansion in core categories can offset some pressure, but investors will demand clearer evidence of durable unit economics without regulatory gray zones driving acquisition

Corrected total cell fluorescence (CTCF) measurement was carried out in ImageJ

14 - Vidal

pilot study) and standard oral Setria glutathione at 500-1,000 mg/day (slower but demonstrated over six months in the Richie et al

Algorithm for thyroid hormone replacement in adults with subclinical hypothyroidism due to Hashimotos thyroiditis 9 *Patients who commence LT4 therapy for symptoms attributed to subclinical hypothyroidism should be reviewed after three or four months to assess response to treatment once the serum TSH returns to the reference range

Head and neck arteries: IgG4-RD can inflame blood vessel walls, potentially causing pain or headaches, especially if blood flow is compromised